Crumly & Associates Inc. Boosts Stock Holdings in Medtronic PLC $MDT

Crumly & Associates Inc. increased its position in shares of Medtronic PLC (NYSE:MDT) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,063 shares of the medical technology company’s stock after acquiring an additional 218 shares during the quarter. Crumly & Associates Inc.’s holdings in Medtronic were worth $616,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in Medtronic during the fourth quarter valued at $756,000. Rafferty Asset Management LLC lifted its holdings in Medtronic by 11.8% during the fourth quarter. Rafferty Asset Management LLC now owns 145,445 shares of the medical technology company’s stock valued at $11,618,000 after purchasing an additional 15,357 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new position in shares of Medtronic in the fourth quarter worth about $1,003,000. Finally, Snowden Capital Advisors LLC lifted its stake in shares of Medtronic by 3.3% in the fourth quarter. Snowden Capital Advisors LLC now owns 43,579 shares of the medical technology company’s stock worth $3,512,000 after buying an additional 1,374 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Activity

In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. This trade represents a 100.00% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

Shares of MDT opened at $94.05 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $96.25. The stock has a market capitalization of $120.64 billion, a P/E ratio of 25.91, a P/E/G ratio of 2.48 and a beta of 0.77. The company’s fifty day moving average is $91.50 and its two-hundred day moving average is $88.28.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. During the same period in the prior year, the company posted $1.23 EPS. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio is presently 78.24%.

Analyst Upgrades and Downgrades

MDT has been the topic of several research reports. BTIG Research reissued a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. Wells Fargo & Company increased their target price on shares of Medtronic from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 20th. Robert W. Baird raised their price objective on shares of Medtronic from $94.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, August 20th. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. Finally, Citigroup lifted their price target on shares of Medtronic from $99.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $102.14.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.